PCSK9 Inhibitor [EPC]

DRUG2 trials

Sponsors

Seoul National University Hospital, GWT-TUD GmbH

Conditions

Aortic Valve StenosisDyslipoproteinemiasFamilial Combined HyperlipidemiaFamilial Hypercholesterolemia - HomozygousHypercholesterolemia, Familial

Phase 2

PCSK9 Inhibitors in the Progression of Aortic Stenosis

Seoul National University HospitalAortic Valve Stenosis

Start: 2017-06-01End: 2020-01-01Target: 140Updated: 2017-02-13

Unknown Phase

Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry

CompletedNCT03110432

GWT-TUD GmbHDyslipoproteinemias, Familial Combined Hyperlipidemia, Familial Hypercholesterolemia - Homozygous +1

Start: 2017-05-18End: 2024-04-17Updated: 2025-05-09

Related Papers

Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies

Clinical Research in Cardiology2025-08-04

Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study.

2025-04-241 citations

Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.

2022-09-305 citations

Heartbeat: therapeutic targets for prevention of calcific aortic valve stenosis

Heart2020-08-26